Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
329 participants
INTERVENTIONAL
2006-12-31
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Grazax in Children
NCT00408616
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment
NCT00773240
Tolerability of Grazax in Patients With Hayfever in Real Life Settings
NCT01433510
A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine
NCT01740284
Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate
NCT01854736
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Grazax
Tablets 75,000 SQT and matching placebo. One tablet daily.
2
Grazax
Tablets 75,000 SQT and matching placebo. One tablet daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Grazax
Tablets 75,000 SQT and matching placebo. One tablet daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive skin prick test to grass
* Positive specific IgE to grass
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ALK-Abelló A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ALK-Abello
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kim Simonsen, MD
Role: STUDY_DIRECTOR
ALK-Abelló A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CompleWare Corporation
Iowa City, Iowa, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Murphy K, Gawchik S, Bernstein D, Andersen J, Pedersen MR. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma. J Negat Results Biomed. 2013 Jun 1;12:10. doi: 10.1186/1477-5751-12-10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GT-14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.